A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Breaking Into Industry: Career Opportunities for PhD Graduates in Analytical Sciences ...

GLP-1 drugs such as Wegovy, Ozempic and Mounjaro are transforming weight loss and reshaping the food industry - driving ...

Ozempic is FDA-approved for treating type 2 diabetes – but could it also help with other conditions like PCOS Read on to find out what an expert says ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle. First, a large-scale real-world study reporting no significantly higher risk of cancer ...

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an ...